Atomera Incorporated Provides First Quarter Update LOS

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
149
Atomera Incorporated Provides First Quarter Update

LOS GATOS, CA--(Marketwired - May 2, 2017) - Atomera Incorporated ("Atomera" or the "Company") ( NASDAQ : ATOM ), a semiconductor materials and intellectual property licensing company focused on deploying its proprietary technology into the semiconductor industry, today provided a corporate update and announced results for the first quarter ended March 31, 2017.

First Quarter Highlights

  • Entered evaluation phase with one top-tier semiconductor manufacturer and entered into the planning phase with one new prospective customer. Atomera now has four potential customers in the pivotal phase of evaluating MST ® .
  • Atomera's new R&D infrastructure is starting to show results with eight wafer fabrication and test cycles completed in the last quarter.

Management Commentary

"The last few months have been extraordinarily productive for Atomera," commented Scott Bibaud, President and CEO. "We are now working with 40% of the world's largest semiconductor manufacturers and have made significant progress with technology advancements that should help us shorten the sales cycle," added Mr. Bibaud.

First Quarter Financial Results

During the first quarter of 2017, the Company incurred a net loss of $3.5 million, or ($0.29) per share, compared to a net loss of $3.4 million, or ($0.28) per share, in the fourth quarter of 2016, and a net loss of $2.5 million, or ($1.54) per share, for the first quarter of 2016. Adjusted EBITDA (a non-GAAP financial measure) in the first quarter of 2017 was a loss of $2.4 million compared to an adjusted EBITDA loss in the fourth quarter of 2016 of $2.1 million, and an adjusted EBITDA loss of $1.9 million in the first quarter of 2016. 

The Company had $23.8 million in cash and cash equivalents as of March 31, 2017, compared to $26.7 million as of December 31, 2016.

The total number of shares outstanding was 12,104,737 as of March 31, 2017.

First Quarter 2017 Conference Call and Webcast

Atomera will host a conference call to discuss its financial results and recent progress. Date: Tuesday, May 2, 2017

Time: 1:30 p.m. PT (4:30 p.m. ET)

Phone: (844) 263-8318 (domestic); +1 (213) 358-0960 (international)

Replay: Available until May 9, 2017 (855) 859-2056 (domestic); +1 (404) 537-3406 (international); passcode 2390715.

Webcast: Accessible at www.atomera.com

Note about NonGAAP Financial Measures

In addition to the unaudited results presented in accordance with generally accepted accounting principles, or GAAP, in this press release, Atomera presents adjusted EBITDA, which is a nonGAAP financial measure. Adjusted EBITDA is determined by taking net loss and eliminating the impacts of interest, taxes, depreciation, amortization, stockbased compensation and the change in fair value of derivative liabilities. Our definition of adjusted EBITDA may not be comparable to the definitions of similarlytitled measures used by other companies. We believe that this nonGAAP financial measure, viewed in addition to and not in lieu of its reported GAAP results, provides useful information to investors by providing a more focused measure of operating results. This metric is used as part of the Company's internal reporting to evaluate its operations and the performance of senior management. A table reconciling this measure to the comparable GAAP measure is available in the accompanying financial tables below.

About Atomera Incorporated

Atomera Incorporated has developed Mears Silicon Technology™ ("MST ® "), which increases performance and power efficiency in semiconductor transistors. MST ® can be implemented using equipment already deployed in semiconductor manufacturing facilities and is complementary to other nanoscaling technologies already in the semiconductor industry roadmap.

Safe Harbor

This press release contains forwardlooking statements concerning Atomera Incorporated, including statements regarding the prospects for the semiconductor industry generally and the ability of our MST® technology to significantly improve semiconductor performance. Those forwardlooking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (1) the fact that we have not yet commenced revenue producing operations or entered into a definitive agreement with regard to the licensing or commercialization of our MST technology, thus subjecting us to all of the risks inherent in a prerevenue enterprise; (2) risks related to our ability to raise sufficient capital, as and when needed, to pursue the further development, licensing and commercialization of our MST ® technology; (3) our ability to protect our proprietary technology, trade secrets and knowhow, and (4) those other risks disclosed in the section "Risk Factors" included in our Annual Report on Form 10-K for the year ended December, 2016 filed with the SEC on March 31, 2017. We caution readers not to place undue reliance on any forwardlooking statements. We do not undertake, and specifically disclaim any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

 
Atomera Incorporated
Condensed Balance Sheets
(in thousands, except per share data)
 
    March 31,     December 31,  
    2017     2016  
      (Unaudited)          
                 
ASSETS                
                 
Current Assets:                
  Cash and cash equivalents   $ 23,812     $ 26,718  
  Prepaid expenses and other current assets     308       96  
    Total current assets     24,120       26,814  
                 
Property and equipment, net     31       28  
Security Deposit     37       37  
                 
    Total assets   $ 24,188     $ 26,879  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY                
                 
Current liabilities:                
  Accounts payable   $ 295     $ 353  
  Accrued expenses     200       168  
  Accrued payroll related expenses     179       510  
                   
    Total liabilities     674       1,031  
                   
    Commitments and contingencies                
                 
Stockholders' equity:                
  Preferred stock, $0.001 par value, authorized 2,500 shares; none issued and outstanding at March 31, 2017 and December 31, 2016     -       -  
  Common stock, $0.001 par value, authorized 47,500 shares; 12,105 shares issued and outstanding at March 31, 2017 and 12,025 issued and outstanding as of December 31, 2016     12       12  
  Additional paid-in capital     123,043       121,833  
  Accumulated deficit     (99,541 )     (95,997 )
    Total stockholders' equity     23,514       25,848  
                     
    Total liabilities and stockholders' equity   $ 24,188     $ 26,879  
                 
                 
 
Atomera Incorporated
Condensed Statements of Operations
(Unaudited)
(in thousands, except per share data)
 
    Three Months Ended March 31,  
    2017     2016  
Operating Expenses:                
  Research and development   $ 1,456     $ 949  
  General and administrative     1,603       861  
  Selling and marketing     509       119  
    Total operating expenses   $ 3,568     $ 1,929  
                 
      Loss from operations     (3,568 )     (1,929 )
                 
Other income/(expense):                
  Interest income     28       --  
  Interest expense             (562 )
  Other expense     (4 )     --  
    Total other expense, net     24       (562 )
                 
Net loss:   $ (3,544 )   $ (2,491 )
                 
Net loss per common share, basic and diluted   $ (0.29 )   $ (1.54 )
                 
  Weighted average number of common shares outstanding, basic and diluted     12,034       1,617  
                 
                 
 
Atomera Incorporated
Reconciliation to Non-GAAP Adjusted EBITDA
(Unaudited)
(in thousands)
 
    Three Months Ended March 31,
    2017   2016
Net Loss (GAAP)   $ (3,544 )   $ (2,491 )
Add (subtract) the following items:                
  Interest income     (28 )     --  
  Interest expense     --       562  
  Depreciation and amortization     5       3  
  Stock-based compensation     1,210       60  
Adjusted EBITDA (non-GAAP)   $ (2,357 )   $ (1,866 )
                 
                 

Investor Contacts: Frank Laurencio CFO 408.442.5246 Email Contact Nick Kormeluk Investor Relations 949.500.0003 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 180

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 410

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 298

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 254

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 317

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 343

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 409

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 250

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 353

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 229

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading

Top 5 Most Recently Viewed Articles

Novartis Fabhalta® Breakthrough in PNH Treatment Showcased

Updated Category News Views 290

Novartis Fabhalta® Achieves Significant Hemoglobin Improvements In recent studies, Novartis has showcased promising results from its Phase IIIB APPULSE-PNH study regarding Fabhalta (iptacopan), designed for adult patients suffering from paroxysmal nocturnal hemoglobinuria (PNH). Patients who switched from anti-C5 therapies demonstrated noteworthy improvement in their...

Continue Reading
Insights into Indonesia's Economic Landscape for Credit Investors

Updated Category News Views 208

Understanding Indonesia's Market Dynamics This week, Gimme Credit unveiled a new Indonesia Country Report that delves into the recent fluctuations in the equity market and its potential ripple effects on foreign exchange and bond markets. The inquiry raises fundamental questions about whether these shifts could necessitate a higher risk premium for those investing in...

Continue Reading
Pliant Therapeutics to Showcase Innovations at Key Healthcare Conference

Updated Category News Views 187

Introduction to Pliant Therapeutics' Participation Pliant Therapeutics, Inc. (NASDAQ: PLRX), a dedicated force in the clinical-stage biotechnology sector, is set to make waves at an upcoming healthcare conference. The event serves as a platform for the company to showcase its integrin-based therapeutics—game-changing innovations aimed at treating various serious health...

Continue Reading
OSB Group PLC Financial Performance Overview for 2025

Updated Category News Views 322

OSB Group PLC Trading Update Summary OSB GROUP PLC, a specialist lending and retail savings group, is pleased to share its trading update for the nine-month period concluding on 30 September 2025. This report highlights the Group's steady growth and enhanced financial performance in line with expectations and strategic objectives. Performance Insights for the Nine-Month...

Continue Reading
Toll Brothers Unveils Luxurious Homes at Ridge Pointe Estates

Updated Category News Views 222

Toll Brothers Unveils New Luxury Homes at Ridge Pointe Estates Toll Brothers, Inc. (NYSE: TOL), recognized as a leader in the luxury home construction industry, has introduced its latest community, Ridge Pointe Estates. This community, now officially open, offers prospective homeowners a blend of elegance and modern living. Located within a serene setting, Ridge Pointe...

Continue Reading